secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2022-03-03T23:59:59+00:00
Accession:  0001193125-22-063699
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Oncology hires Jeffrey Jones as CMO and appoints Anne-Marie Martin to board
--------------------------------------------------------------------------------

- Jeffrey Jones, M.D., MPH, MBA, appointed CMO effective Feb 28, 2022; previously VP at Bristol Myers Squibb.
- Annual base salary $460,000; sign-on bonus $100,000; option for 215,000 shares at $14.34.
- Dr. Jones' option vests 25% on first anniversary, remainder monthly over three years.
- Anne-Marie Martin, Ph.D., appointed Class I director effective Mar 1, 2022; SVP at GlaxoSmithKline.
- Dr. Martin received option grant with grant-date fair value $350,000 vesting over three years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000119312522063699/0001193125-22-063699-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000119312522063699/d303753d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-063699

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer